Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.045|
|52 Week High||AU$0.035|
|52 Week Low||AU$0.14|
|1 Month Change||12.50%|
|3 Month Change||-4.26%|
|1 Year Change||-43.04%|
|3 Year Change||-29.69%|
|5 Year Change||n/a|
|Change since IPO||95.65%|
Recent News & Updates
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
|ZLD||AU Pharmaceuticals||AU Market|
Return vs Industry: ZLD underperformed the Australian Pharmaceuticals industry which returned 5.8% over the past year.
Return vs Market: ZLD underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: ZLD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ZLD's weekly volatility (9%) has been stable over the past year.
About the Company
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia.
Zelira Therapeutics Fundamentals Summary
|ZLD fundamental statistics|
Is ZLD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ZLD income statement (TTM)|
|Cost of Revenue||AU$228.22k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0072|
|Net Profit Margin||-1,288.84%|
How did ZLD perform over the long term?See historical performance and comparison
Is Zelira Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ZLD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ZLD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ZLD is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: ZLD is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ZLD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ZLD is good value based on its PB Ratio (1.4x) compared to the AU Pharmaceuticals industry average (3.5x).
How is Zelira Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zelira Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Zelira Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZLD is currently unprofitable.
Growing Profit Margin: ZLD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 27% per year.
Accelerating Growth: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: ZLD has a negative Return on Equity (-22.6%), as it is currently unprofitable.
How is Zelira Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ZLD's short term assets (A$6.1M) exceed its short term liabilities (A$1.1M).
Long Term Liabilities: ZLD's short term assets (A$6.1M) exceed its long term liabilities (A$460.6K).
Debt to Equity History and Analysis
Debt Level: ZLD is debt free.
Reducing Debt: ZLD currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZLD has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ZLD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.5% each year
What is Zelira Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ZLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZLD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZLD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZLD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Oludare Odumosu serves as Director of Zelira Therapeutics Limited (formerly Zelda Therapeutics Ltd) since December 02, 2019. He serves as the Managing Director & Global Chief Executive Officer of Zelir...
CEO Compensation Analysis
Compensation vs Market: Oludare's total compensation ($USD418.41K) is above average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Oludare's compensation has increased whilst the company is unprofitable.
Experienced Management: ZLD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: ZLD's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Zelira Therapeutics Limited's employee growth, exchange listings and data sources
- Name: Zelira Therapeutics Limited
- Ticker: ZLD
- Exchange: ASX
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$53.565m
- Shares outstanding: 1.19b
- Website: https://www.zeliratx.com
- Zelira Therapeutics Limited
- 101 St Georges Terrace
- Level 3
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:34|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.